Log in

OTCMKTS:RNUGFReNeuron Group Stock Price, Forecast & News

$1.78
0.00 (0.00 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.78
Now: $1.78
$1.78
50-Day Range
$1.75
MA: $1.79
$1.98
52-Week Range
$0.95
Now: $1.78
$3.29
VolumeN/A
Average Volume244 shs
Market Capitalization$56.66 million
P/E RatioN/A
Dividend YieldN/A
Beta-26.14
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Read More
ReNeuron Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RNUGF
Previous SymbolNASDAQ:RNUGF
CUSIPN/A
CIKN/A
Phone44-0-20-3819-8400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60,000.00

Profitability

Miscellaneous

Employees62
Market Cap$56.66 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RNUGF News and Ratings via Email

Sign-up to receive the latest news and ratings for RNUGF and its competitors with MarketBeat's FREE daily newsletter.

ReNeuron Group (OTCMKTS:RNUGF) Frequently Asked Questions

How has ReNeuron Group's stock been impacted by COVID-19 (Coronavirus)?

ReNeuron Group's stock was trading at $1.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RNUGF shares have increased by 1.7% and is now trading at $1.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ReNeuron Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ReNeuron Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ReNeuron Group.

What price target have analysts set for RNUGF?

1 Wall Street analysts have issued twelve-month price objectives for ReNeuron Group's stock. Their forecasts range from $6.00 to $6.00. On average, they expect ReNeuron Group's stock price to reach $6.00 in the next year. This suggests a possible upside of 237.1% from the stock's current price. View analysts' price targets for ReNeuron Group.

Has ReNeuron Group been receiving favorable news coverage?

Media stories about RNUGF stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ReNeuron Group earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about ReNeuron Group.

Who are some of ReNeuron Group's key competitors?

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the OTCMKTS under the ticker symbol "RNUGF."

How do I buy shares of ReNeuron Group?

Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ReNeuron Group's stock price today?

One share of RNUGF stock can currently be purchased for approximately $1.78.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of $56.66 million and generates $60,000.00 in revenue each year. ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-0-20-3819-8400.

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.